The company said total revenues for Q4 2024 rose 11% from Q4 2023 to $9.1 billion, and full-year total revenues rose 19% from 2023 to $33.4 billion.

1. 01

   The company said total revenues for Q4 2024 rose 11% from Q4 2023 to $9.1 billion, and full-year total revenues rose 19% from 2023 to $33.4 billion.

2. 02

   Amgen said full-year GAAP EPS fell 39% from $12.49 to $7.56, while non-GAAP EPS rose 6% from $18.65 to $19.84. The company cited higher operating expenses, including amortization of Horizon acquisition-related assets, and losses on its equity investments as factors in the GAAP EPS decline.

3. 03

   The company said free cash flow for 2024 was $10.4 billion, compared with $7.4 billion in 2023, and that Q4 was $4.4 billion. It cited business performance and the timing of working capital items, primarily collections, as factors.

4. 04

   The company expects full-year 2025 total revenues of $34.3 billion to $35.7 billion, non-GAAP EPS of $20.00 to $21.20, capital expenditures of about $2.3 billion, and share repurchases of up to $500 million.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.